Journal of Medicinal Chemistry · 2020 · 19 citations · 22 references
PharmacyMedicinal ChemistryOncologyDrug DesignDrug DiscoveryMolecular OncologyCovalent Inhibitor DesignEnzyme InhibitionLigand BindingPotency OptimizationAnticancer Compound ScreeningCovalent InhibitorsHer2 AmplificationHer2 InhibitorsHer2 Receptor TargetingLead Compound ScreeningNon-small Cell Lung Cancer TreatmentSmall Molecule Tyrosine Kinase Inhibitors
Mutated or amplified Her2 serves as a driver of non-small cell lung cancer or mediates resistance toward the inhibition of its family member epidermal growth factor receptor with small-molecule inhibitors. To date, small-molecule inhibitors targeting Her2 which can be used in clinical routine are lacking, and therefore, the development of novel inhibitors was undertaken. In this study, the well-established pyrrolopyrimidine scaffold was modified with structural motifs identified from a screening campaign with more than 1600 compounds, which were applied against wild-type Her2 and its mutant variant Her2-A775_G776insYVMA. The resulting inhibitors were designed to covalently target a reactive cysteine in the binding site of Her2 and were further optimized by means of structure-based drug design utilizing a set of obtained complex crystal structures. In addition, the analysis of binding kinetics and absorption, distribution, metabolism, and excretion parameters as well as mass spectrometry experiments and western blot analysis substantiated our approach.
22
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene · 2008 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +11
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia, Cai‐Hong Yun, Eunyoung Park et al. · Nature · 2016 · 879 citations · Full text
Medicine, Oncology, Pharmacology +11